ReviewCurrent radiopharmaceuticals2025
Harnessing Radionuclides: Unveiling the Promising Role of Radiopharmaceuticals in Cancer Theranostics and Palliative Care.
Review in Current radiopharmaceuticals, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrating digital solutions improves mental health management in cancer care.Communications medicine · 2026Review
- Targeting Glypican-3 in Liver Cancer: Groundbreaking Preclinical and Clinical Insights.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn the context of modern oncology, radiogenic elements have emerged as pivotal tools for targeted cancer therapies. Elements like Iodine-131 and Yttrium-90 offer unique radiological properties that allow precise treatment delivery. This article explores their growing importance and potential in reshaping the landscape of cancer therapy.
methodsUtilizing a systematic literature search, relevant studies, clinical trials, and research articles were collected from databases. The selected material was scrutinized to extract insights into the mechanisms, applications, advantages, and challenges of radiogenic elements. These results are combined in the study to give a perceptive picture of how contemporary oncology treatment is developing.
resultsThe article reveals a comprehensive analysis of the outcomes derived from the study of radiogenic elements in contemporary cancer treatment. The results highlight the diverse applications of radionuclides like Iodine-131, Yttrium-90, and actinides in targeted therapies. It showcases their ability to selectively damage cancer cells while sparing healthy tissues, emphasizing precision and efficacy. The review underscores the increasing importance of personalized medicine, combination therapies, and the potential of emerging alpha-particle-based treatments. Furthermore, the results shed light on the challenges posed by radiation safety and potential side effects, prompting a need for vigilant management. This comprehensive examination of results provides a nuanced understanding of the pivotal role that radiogenic elements play in shaping the future of modern oncology therapy.
conclusionThe article examines the role of radiogenic elements in contemporary cancer treatment. It highlights the significance of elements like 131I, 90Y, and actinides in targeted therapies, discussing their mechanisms and applications. The article emphasizes personalized medicine, combination therapies, and emerging alpha-particle-based treatments. Challenges, including radiation safety and side effects, are also addressed. The review anticipates a promising future where radiogenic elements contribute to precise, effective, and patient-centered cancer care.
Indexed as
Identifiers
39844415What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.